

CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS

Nonsteroidal Anti- Inflammatory Drugs for Chronic Pain in Pediatric Populations: Clinical Effectiveness

Service Line: Rapid Response Service
Version: 1.0
Publication Date: May 1, 2020
Report Length: 6 Pages

Authors: Deba Hafizi, Chris Freige, Suzanne McCormack

Cite As: Nonsteroidal Anti-Inflammatory Drugs for Chronic Pain in Pediatric Populations: Clinical Effectiveness. Ottawa: CADTH; 2020 May. (CADTH rapid response report: summary of abstracts).

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to requests@cadth.ca

Research Question

What is the clinical effectiveness of nonsteroidal anti-inflammatory drugs for the treatment of chronic pain in pediatric patients?

Key Findings

Five systematic reviews were identified regarding the clinical effectiveness of nonsteroidal anti-inflammatory drugs for the treatment of chronic pain in pediatric patients.

Methods

A limited literature search was conducted by an information specialist on key resources including Medline, the Cochrane Library, the University of York Centre for Reviews and Dissemination (CRD) databases, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were NSAIDs and chronic pain in the pediatric population. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between Jan 1, 2015 and Apr 16, 2020. Internet links were provided, where available.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

Population	Pediatric patients with chronic pain, including pain from chronic daily headaches, migraines, back pain, abdominal pain, idiopathic local pain, chronic widespread pain and fibromyalgia, and complex regional pain syndrome
Intervention	Nonsteroidal anti-inflammatory drugs (e.g., ibuprofen, naproxen, ketorolac)
Comparator	Other pharmacological medications (e.g., gabapentin, pregabalin, amitriptyline, nortriptyline, duloxetine, acetaminophen) Placebo Non-pharmacological interventions (e.g., physiotherapy, exercise, counseling, neurostimulation)

Outcomes	Clinical effectiveness (e.g., change in pain symptoms, change in quality of life, functional outcomes, disability)
Study Designs	Health technology assessments, systematic reviews, randomized controlled trials, non-randomized studies

Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, and systematic reviews are presented first and are followed by randomized controlled trials and non-randomized studies.

Five systematic reviews¹⁻⁵ (one overview of systematic reviews¹ and another overview of systematic reviews with meta-analysis⁵) were identified regarding the clinical effectiveness of non-steroidal anti-inflammatory drugs for the treatment of chronic pain in pediatric patients. No relevant health technology assessments, randomized controlled trials, or non-randomized studies were identified.

Additional references of potential interest are provided in the appendix.

Overall Summary of Findings

Five systematic reviews¹⁻⁵ (one overview of systematic reviews¹ and another overview of systematic reviews with meta-analysis⁵) were identified regarding the clinical effectiveness of nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of chronic pain in pediatric patients. The authors of the identified overview of systematic reviews¹ found no evidence from randomized controlled trials (RCTs) that NSAIDs, such as ibuprofen, were effective for chronic non-cancer pain in children and adolescents.¹ Consequently the authors of another systematic review² aimed to assess the analgesic efficacy, and adverse events, of NSAIDs used to treat cancer-related pain in children and adolescents and also found no evidence. The same authors conducted another systematic review³ aimed at reviewing the efficacy and safety of utilizing NSAIDs to treat chronic non-cancer pain in children and adolescents and identified seven RCTs. However, the data was insufficient and the authors could not draw any conclusions about the efficacy or harm of NSAIDs on chronic non-cancer pain.³ The authors of another systematic review⁴ aimed to assess the effects of pharmacological interventions such as NSAIDs versus placebo for the treatment of migraines in children and adolescents. The authors identified two low quality trials, concluding that ibuprofen was more effective than placebo for relieving pain, while another trial found that sumatriptan plus naproxen sodium was also effective in treating adolescents with migraine.⁴ The authors also made note that there was limited information available on adverse events related to ibuprofen use.⁴ The last identified overview of systematic reviews with meta-analysis⁵ concluded that ibuprofen at conventional doses was consistently superior to paracetamol at providing pain relief for a range of painful conditions including osteoarthritis, rheumatoid arthritis, migraines, and back pain.

References Summarized

Health Technology Assessments

No literature identified.

Systematic Reviews and Meta-analyses

1. Radman M, Babic A, Runjic E, et al. Revisiting established medicines: An overview of systematic reviews about ibuprofen and paracetamol for treating pain in children. *Eur J Pain*. 2019 Jul;23(6):1071-1082.
[PubMed: PM30793444](#)
2. Cooper TE, Heathcote LC, Anderson B, Gregoire MC, Ljungman G, Eccleston C. Non-steroidal anti-inflammatory drugs (NSAIDs) for cancer-related pain in children and adolescents. *Cochrane Database Syst Rev*. 2017 07 24;7:CD012563.
[PubMed: PM28737843](#)
3. Eccleston C, Cooper TE, Fisher E, Anderson B, Wilkinson NM. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. *Cochrane Database Syst Rev*. 2017 08 02;8:CD012537.
[PubMed: PM28770976](#)
4. Richer L, Billingham L, Linsdell MA, et al. Drugs for the acute treatment of migraine in children and adolescents. *Cochrane Database Syst Rev*. 2016 Apr 19;4:CD005220.
[PubMed: PM27091010](#)
5. Moore RA, Derry S, Wiffen PJ, Straube S, Aldington DJ. Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. *Eur J Pain*. 2015 Oct;19(9):1213-1223.
[PubMed: PM25530283](#)

Randomized Controlled Trials

No literature identified.

Non-Randomized Studies

No literature identified.

Appendix — Further Information

Previous CADTH Reports

6. Pain Management Programs for Pediatric Patients with Chronic Pain Conditions: Clinical Effectiveness, Cost Effectiveness, and Guidelines. (*CADTH Rapid Response report: summary of abstracts*). Ottawa (ON): CADTH; 2020: <https://www.cadth.ca/pain-management-programs-pediatric-patients-chronic-pain-conditions-clinical-effectiveness-cost>
7. Research Gaps: Chronic Pain Management: Non-Pharmacological Treatments. (*CADTH Tools*). Ottawa (ON): CADTH; 2018: <https://www.cadth.ca/tools/research-gaps-chronic-pain-management-non-pharmacologic-treatments>
8. Evidence on Pain Management. Ottawa (ON): CADTH; 2020. <https://www.cadth.ca/evidence-bundles/pain-evidence-bundle>

Randomized Controlled Trials

Alternative Comparator

9. Patel JC, Patel PB, Acharya H, Nakum K, Tripathi CB. Efficacy and safety of lornoxicam vs ibuprofen in primary dysmenorrhea: a randomized, double-blind, double dummy, active-controlled, cross over study. *Eur J Obstet Gynecol Reprod Biol*. 2015 May;188:118-123. [PubMed: PM25808572](#)

Age Unspecified

10. Yousefi M, Kavianpour M, Hesami S, Rashidi Nooshabadi M, Khadem Haghghian H. Effect of alpha-lipoic acid at the combination with mefenamic acid in girls with primary dysmenorrhea: randomized, double-blind, placebo-controlled clinical trial. *Gynecol Endocrinol*. 2019 Sep;35(9):782-786. [PubMed: PM30957578](#)

Review Articles

11. Barbagallo M, Sacerdote P. Ibuprofen in the treatment of children's inflammatory pain: a clinical and pharmacological overview. *Minerva Pediatr*. 2019 Feb;71(1):82-99. [PubMed: PM30574736](#)
12. Caes L, Fisher E, Clinch J, Eccleston C. Current Evidence-Based Interdisciplinary Treatment Options for Pediatric Musculoskeletal Pain. *Curr Treatm Opt Rheumatol*. 2018;4(3):223-234. [PubMed: PM30148046](#)

Additional References

13. Reid K, Hartling L, Ali S, Le A, Norris A, Scott SD. Development and Usability Evaluation of an Art and Narrative-Based Knowledge Translation Tool for Parents With a Child With Pediatric Chronic Pain: Multi-Method Study. *J Med Internet Res*. 2017 12 14;19(12):e412. [PubMed: PM29242180](#)